RESUMO
Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence. It is a prodrug for oral administration with intracellular activation. It is activatedin liver cells and to a lesser extent in kidney cells, being absent in adipose tissue and muscle cells. Therefore, unlike statins, its potential myotoxic effect is very limited. It has recently been approved as a lipid-lowering drug in combination with diet, with statins, or with other lipid-lowering drugs in patients with hypercholesterolaemia, mixed dyslipidaemia, statin intolerance, or when these are contraindicated. The marketing of bempedoic acid implies, in clinical practice, having a new family of lipid-lowering drugs.
Assuntos
Ácidos Dicarboxílicos/administração & dosagem , Dislipidemias/tratamento farmacológico , Ácidos Graxos/administração & dosagem , Hipolipemiantes/administração & dosagem , Ácidos Dicarboxílicos/farmacocinética , Ácidos Dicarboxílicos/farmacologia , Quimioterapia Combinada , Ácidos Graxos/farmacocinética , Ácidos Graxos/farmacologia , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Hipercolesterolemia/tratamento farmacológico , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacologiaRESUMO
No disponible
Assuntos
Humanos , Infecções por HIV/complicações , Doenças Cardiovasculares/epidemiologia , Fatores de Risco , Risco AjustadoRESUMO
No disponible
